BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 37923899)

  • 1. DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma.
    Lu Y; Wang S; Chi T; Zhao Y; Guo H; Wang H; Feng L
    Sci Rep; 2023 Nov; 13(1):18978. PubMed ID: 37923899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma.
    Lin Z; Xu Q; Miao D; Yu F
    Front Oncol; 2021; 11():644416. PubMed ID: 33828988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
    Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
    Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
    Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
    Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
    Li X; Lin J; Pan Y; Cui P; Xia J
    Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
    Yan Z; He M; He L; Wei L; Zhang Y
    Front Immunol; 2021; 12():723271. PubMed ID: 34925311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
    Wang Y; Song F; Zhang X; Yang C
    Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
    Gao S; Zhang L; Wang H
    Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT‒qPCR validation.
    Guan R; Zou J; Mei J; Deng M; Guo R
    BMC Cancer; 2022 Jul; 22(1):830. PubMed ID: 35907846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cuproptosis-related molecular classification and gene signature of hepatocellular carcinoma and experimental verification.
    Chen Z; Du D; Li J; Zhang W; Shao J
    Transl Cancer Res; 2024 Mar; 13(3):1268-1289. PubMed ID: 38617510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
    Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
    BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
    Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
    Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening and identification of angiogenesis-related genes as potential novel prognostic biomarkers of hepatocellular carcinoma through bioinformatics analysis.
    Zhen Z; Shen Z; Hu Y; Sun P
    Aging (Albany NY); 2021 Jul; 13(13):17707-17733. PubMed ID: 34252885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis.
    Wang W; Pan F; Lin X; Yuan J; Tao C; Wang R
    Front Genet; 2022; 13():907331. PubMed ID: 35938001
    [No Abstract]   [Full Text] [Related]  

  • 17. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma.
    Huang F; Zhang C; Yang W; Zhou Y; Yang Y; Yang X; Guo W; Wang B
    BMC Genomics; 2024 Feb; 25(1):155. PubMed ID: 38326754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying the predictive role and the related drugs of oxidative stress genes in the hepatocellular carcinoma.
    Nie G; Zhu X; Zhang H; Wang H; Yan J; Li X
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e1978. PubMed ID: 38599581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
    Chen S; Zhao E
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.